Breast Cancer Liver Metastasis
Conditions
Interventions
Control group:Transhepatic arterial chemoembolization.
Dobilococin hydrochloride injection 20mg/m^2, configured with 5% glucose injection.
Research group:Injectable melphalan hydrochloride combined with transhepatic arterial chemoembolization.
Dobilococin hydrochloride injection 20mg/m^2, configured with 5% glucose injection. Melphalan h
Sponsors
Nanchang People's Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Female patients aged 18-70 years; 2.Patients with a previous pathological diagnosis of breast cancer are diagnosed with luminal breast cancer and have liver metastases. 3.Pathologically confirmed HER2-negative breast cancer; 4.Child-Pugh class A of liver function or better class B (= 70 points and a performance status score of 3 months; 8.Voluntary participation with signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Triple-negative breast cancer; 2.The existence of severe liver and kidney dysfunction; 3.There are obvious contraindications to interventional therapy: obvious arteriovenous fistula; uncorrectable coagulation dysfunction and obvious blood abnormalities, with obvious bleeding tendency; persistent large amount of ascites; 4.Combined active infection, especially inflammation of bile duct system; 5.Pregnant or lactating female patients, female patients of childbearing potential with a positive baseline pregnancy test or female patients of childbearing potential who are unwilling to use effective contraception throughout the trial period; 6.In the judgment of the investigator, a serious concomitant disease that jeopardizes the patient's safety, or interferes with the patient's ability to complete the study (including, but not limited to, severe hypertension that cannot be controlled by medication, severe diabetes, etc. 7.Any other condition that, in the judgment of the investigator, makes the patient unsuitable for participation in this study; 8.Patients with allergies or relevant contraindications to the components of the experimental drug or any excipients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Progression-free survival;Disease control rate; | — |
Countries
China
Contacts
Public ContactLiu Shengshan, Wang Hong
Nanchang People's Hospital
Outcome results
None listed